Trump Rages Against Novo: ‘Fools!’

U.S. President Donald Trump has once again launched an attack against the high prices of the pharmaceutical industry – this time directly targeting Danish company Novo Nordisk.

During a press conference at the White House with Health Secretary Robert F. Kennedy at his side, Trump named one of the industry’s major players.

Ozempic at the Center of Price Wars

Trump criticized the popular weight loss drug Ozempic, which is produced by Novo Nordisk, accusing the company of charging exorbitant prices to American consumers. ‘Ozempic costs 10 times more in the U.S. than in third-world countries. Why is that? What have we done? Fools!’ the president exclaimed.

The comment was part of a broader critique of what Trump calls ‘the world’s most powerful lobbying organization.’

Immediate Signing of Price Reform

Before the press conference concluded, Trump returned to the podium to sign a new decree aimed at lowering drug prices.

The initiative, titled ‘equalize,’ is intended, according to the president, to bring American prices in line with the rest of the world – in some cases reducing them by up to 90 percent. ‘I am doing this for the American people,’ Trump declared as he signed his name.

From Trade War to Health War

The decree coincides with a new, temporary trade agreement with China, where both countries have significantly reduced tariffs.

Market Turbulence

Trump also announced that the U.S. will no longer subsidize medicine produced abroad.

With Novo Nordisk as one of the largest foreign suppliers to the American market, the statements immediately caused market turmoil – Novo’s stock fell noticeably.

The president’s words alone seem to have the power to move markets, and the message is clear: foreign pharmaceutical giants are no longer welcome to a free-for-all in the American market.

Our team may have used AI to assist in the creation of this content, which has been reviewed by our editors.